120891-35-2

Upstream product

• 120891-43-2 {(Z)-4-[(1R,2R,3R,5S)-2-[(E)-(S)-3-Cyclohexyl-3-(tetrahydro-pyran-2-yloxy)-propenyl]-5-hydroxy-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-but-2-enyloxy}-acetic acid tert-butyl ester 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 130172-78-0 (Z)-4-[(1R,2R,3R,5S)-5-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-cyclohexyl-3-(tetrahydro-pyran-2-yloxy)-propenyl]-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-but-2-enoic acid methyl ester 

Downstream Products

• 130172-79-1 {(Z)-4-[(4R,5R)-5-((E)-(S)-3-Cyclohexyl-3-hydroxy-propenyl)-4-hydroxy-cyclopent-1-enyl]-but-2-enyloxy}-acetic acid tert-butyl ester 
• 120891-34-1 ZK 118882 
• 120891-44-3 ZK 118182 

Relevant academic research and scientific papers

Synthesis of a chemically and metabolically stable and biologically potent PGD2-analogue

The metabolic labile α-chain of the PGD2-analogue 2 (ZK 110841) can be stabilized by introduction of an β-oxygen-atom resulting in 3 (ZK 118182), which has a much higher and longer lasting biological activity on oral application in rats. The synthetic methodology for the synthesis of 3-oxa-Z-Δ5,6-prostaglandins will be discussed.